Chilov Michael N, Grigg John R, Playfair T Justin
Sydney Eye Hospital, and Save Sight Institute, Sydney, New South Wales, Australia.
Clin Exp Ophthalmol. 2007 Jul;35(5):494-6. doi: 10.1111/j.1442-9071.2007.01521.x.
Herein three cases of angle closure secondary to neovascularization (elevated intraocular pressure in two of the cases) treated with the anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab (Avastin) are reported. In all three cases there was rapid resolution of neovascularization and control of intraocular pressure. One patient with corneal anaesthesia from diabetes developed infectious keratitis, potentially as a consequence of inhibition of VEGF wound healing and neurotrophic functions. Avastin appears to have a promising role in the treatment of neovascular glaucoma but is not without potential local and systemic side-effects.
本文报告了3例继发于新生血管形成的闭角型青光眼（其中2例眼压升高），采用抗血管内皮生长因子（VEGF）单克隆抗体贝伐单抗（阿瓦斯汀）治疗的病例。在所有3例病例中，新生血管迅速消退，眼压得到控制。1例患有糖尿病性角膜麻醉的患者发生了感染性角膜炎，这可能是抑制VEGF伤口愈合和神经营养功能的结果。阿瓦斯汀在新生血管性青光眼的治疗中似乎具有广阔前景，但并非没有潜在的局部和全身副作用。
